Recent data suggest a paraneoplastic mechanism of scleroderma pathogenesis in unique subsets of scleroderma patients. In this article, we review these data, explore potential links between cancer and scleroderma, and propose an approach to malignancy screening in scleroderma.
INTRODUCTION
As in many systemic inflammatory rheumatic conditions, patients with systemic sclerosis (scleroderma) have an elevated risk of cancer compared with the general population. This increased risk could be secondary to damage from scleroderma itself, cytotoxic therapies utilized to treat scleroderma, a common inciting exposure, or a genetic predisposition to the development of both cancer and autoimmunity. Cancer therapies may also trigger severe Raynaud's phenomenon or exaggerated fibrosis reminiscent of scleroderma. Importantly, a subset of patients develops cancer and scleroderma concurrently, suggesting that these two diseases are mechanistically associated. In this article, we will review the epidemiology of cancer in scleroderma and recent data supporting a paraneoplastic mechanism of scleroderma pathogenesis. Finally, we will discuss the implications which these studies may have on the approach to screening scleroderma patients for an underlying malignancy.
SCLERODERMA PATIENTS HAVE AN ELEVATED RISK OF MANY TYPES OF CANCER
Many epidemiological studies [1] [2] [3] [4] [5] [6] 7 & , [8] [9] [10] have demonstrated that patients with scleroderma have an elevated age-adjusted and sex-adjusted risk of cancer compared with the general population. As it is beyond the scope of this review to discuss all of these studies, we will focus on an excellent recently published meta-analysis of populationbased cohort studies summarizing cancer risk in scleroderma [7 & ]. The authors pooled six original studies from Sweden, Scotland, Australia, US, Denmark and Taiwan with a total of 6641 scleroderma patients. Patients with scleroderma had an elevated risk of all cancers [pooled standardized incidence ratio (SIR) 1.41, 95% confidence interval (CI) 1.18, 1.68], and this risk was higher in men (pooled SIR 1.85, 95% CI 1. 49, 2.31) [11, 12] have demonstrated a temporal clustering of scleroderma with breast cancer diagnosis, the risk of breast cancer was not increased in scleroderma compared with the general population. Similarly, there was not an increased risk of other sex-specific tumor types, such as prostate, cervical and uterine cancers. The authors also performed a secondary analysis of data from referral center studies and detected an increased risk of esophageal cancer (SIR 9.59, 95% CI 2.10, 43.88). Other studies [5, 13] have also demonstrated an increased risk of oropharyngeal cancers, with one US study [13] identifying a 25-fold increased incidence of tongue cancer.
It is important to define whether specific demographic or scleroderma phenotypic characteristics associate with an increased risk of cancer in scleroderma as these features may help identify patients who would benefit from targeted malignancy screening. Although the data are controversial, some studies have suggested that the risk of cancer may be higher in patients with diffuse cutaneous disease [4] . Similarly, interstitial lung disease may be a risk factor for lung cancer in scleroderma [1, 14, 15] . Patients developing new onset scleroderma at an older age also have an elevated risk of cancer (see details below) [1, 16, 17] .
POTENTIAL LINKS BETWEEN CANCER AND SCLERODERMA
Patients with scleroderma may have an elevated risk of cancer because of disease activity or treatmentrelated factors [18] . Damage from chronic inflammation and fibrosis may lead to malignant transformation in certain organ systems. For example, ILD may be associated with lung cancer, and patients with severe, refractory gastroesophageal reflux disease and Barrett's esophagus may have a higher risk of esophageal cancers [19] . An overlap syndrome with primary biliary cirrhosis may be seen in scleroderma, particularly among patients with limited cutaneous disease and anticentromere antibodies, and this may be associated with a higher risk of hepatic malignancies [20, 21] . Immunosuppressive therapies used to treat scleroderma may also contribute to cancer risk. For example, mycophenolate mofetil and cyclophosphamide are often used to treat active diffuse cutaneous disease, ILD or myositis in scleroderma. It is well established that an increased cumulative dose exposure to cyclophosphamide raises the risk of bladder and hematologic malignancies [22, 23] . Data on cancer risk with mycophenolate mofetil are primarily available from the organ transplant literature. To date, the findings are controversial, with some suggesting an increased risk of lymphomas and nonmelanoma skin cancers [24] [25] [26] [27] . Complicating interpretation of the effect of mycophenolate use is the fact that these patients are often on combination immunosuppressive therapies.
Although disease factors or scleroderma treatments may contribute to subsequent cancer risk, it is noteworthy that a subset of patients develops scleroderma after their cancer diagnosis. This raises the possibility that cancer therapies themselves may promote the development of scleroderma. Consistent with this hypothesis are case reports suggesting that bleomycin, carboplatin, gemcitabine, and paclitaxel may initiate severe Raynaud's phenomenon, critical digital ischemia, and/or skin fibrosis [28] [29] [30] [31] [32] [33] . Immunotherapies that eradicate tumors by harnessing host immune responses may trigger autoimmunity [34] , and radiation therapy may stimulate the development of localized scleroderma or exacerbate preexisting scleroderma (although whether it could stimulate de-novo scleroderma remains unknown) [35] [36] [37] .
It is intriguing that scleroderma patients frequently have a striking family history of both malignancy and autoimmune diseases; whether this results from a shared genetic susceptibility or environmental exposure, such as silica, that could initiate both diseases awaits elucidation [38, 39] .
KEY POINTS
There is a close temporal relationship between cancer diagnosis and scleroderma onset in a subset of patients, suggesting that these two diseases may be mechanistically linked.
Patients with RNA polymerase III autoantibodies or an older age of scleroderma onset have a higher risk of cancer-associated scleroderma.
Enhanced cancer surveillance and screening may be warranted in patients at risk of cancer-associated scleroderma, as early cancer detection and therapy may improve scleroderma outcomes.
UNIQUE PATIENT SUBSETS HAVE A TEMPORAL CLUSTERING OF CANCER WITH SCLERODERMA ONSET
In some patients, cancer diagnosis and scleroderma onset are coincident temporally. This, together with reports of scleroderma improving with cancer therapy, raises the possibility that scleroderma is a paraneoplastic disease. In the Onishi meta-analysis, the risk of cancer was higher in the first 12 months after scleroderma diagnosis (pooled SIR 2.79, 95% CI 1.81, 4.31) than more than 12 months after scleroderma diagnosis (pooled SIR 1.40, 95% CI 1.22, 1.61; P ¼ 0.003 for comparison) [7 & ]. Consistently with this, we determined that many (22.7%) cancer diagnoses occurred within 2 years of the first non-Raynaud's scleroderma symptom in a recent study [17] of the Johns Hopkins Scleroderma Center cohort ( Fig. 1 ). Although there could be a cancer detection bias in patients with new onset disease, many cancer cases were also diagnosed shortly before the first clinical signs of scleroderma were appreciated.
In an initial pilot study [40 & ] of 23 scleroderma patients with cancer, we demonstrated that patients with RNA polymerase III autoantibodies have a striking temporal clustering of cancer diagnosis with the first clinical signs of scleroderma. Furthermore, these patients had unique nucleolar expression of RNA polymerase III in their cancerous cells that was not detected in patients with other scleroderma autoantibodies or in normal control tissues [40 & ]. These data suggested that scleroderma autoantigen expression in cancer cells was associated with scleroderma-specific immune responses.
The increased risk of concurrent cancer with scleroderma onset among patients with RNA polymerase III antibodies has now been confirmed in four other studies [16, 17, 41, 42] . In an Australian study [16] of 451 scleroderma patients, those with anti-RNA polymerase III antibodies had a 4.2-fold increased odds of cancer within 5 years of scleroderma onset (95% CI 1.3, 13.4). In another investigation of 2177 scleroderma patients in the Royal Free Hospital scleroderma cohort, patients with cancer within 3 years of scleroderma onset were much more likely to be anti-RNA polymerase III antibody-positive (55.3%) than antitopoisomerase 1 (6.3%, P < 0.0001) or anticentromere (6.8%, P < 0.001) positive patients [42] . In our US cohort, we studied 1044 scleroderma patients [17] . Those with RNA polymerase III autoantibodies had a 5.08-fold increased risk of cancer within 2 years of scleroderma onset (95% CI 1.60, 16.1) [17] . An older age of scleroderma onset was also strongly associated with a clustering of cancer with scleroderma [17] . These data suggest that patients with new onset scleroderma and RNA polymerase III autoantibodies, or an older age of scleroderma onset, may benefit from aggressive malignancy screening at diagnosis.
All of these cohorts also had scleroderma patients with contemporaneous cancer and scleroderma onset in other autoantibody groups. For patients with antitopoisomerase 1 antibodies and those who were antinuclear antibody (ANA) positive but negative for centromere, topoisomerase 1, and RNA polymerase III autoantibodies, the clustering of cancer diagnosis with scleroderma onset was most remarkable among patients developing scleroderma at older ages (Fig. 2 ) [17] . There are several possible explanations for the shortening of the cancer-scleroderma interval among older patients developing scleroderma. Patients with a young age of scleroderma onset may develop later cancers because of damage from the disease or therapies used to treat it, whereas patients with an older age of scleroderma onset may have paraneoplastic disease (see below) [17] . Alternatively, patients with a young age of scleroderma onset may be able to mount robust antitumor immune responses that hold subclinical malignancies in equilibrium for years until the cancer mutates and evades the antitumor immune response, thereby resulting in a long cancer-scleroderma interval; in contrast, older patients developing scleroderma may have poorer quality immunosurveillance of malignancies resulting in concurrent emergence of cancer and scleroderma [17] . The data demonstrating a clustering of cancer with scleroderma onset in other autoantibody groups are intriguing and raise the question of whether cancer may be a trigger of autoimmunity more broadly among patients with scleroderma [43] . locus) in tumors may trigger autoimmunity, we studied tumors from eight anti-RNA polymerase III antibody-positive scleroderma patients, and from another eight scleroderma patients with antibodies against either topoisomerase I or centromere proteins [44 && ]. In six of eight (75%) of the anti-RNA polymerase III positive patients, the POLR3A locus was genetically altered. In contrast, no such alterations were found in tumors from the other group of scleroderma patients. In three of six (50%), the genetic alterations we found were somatic mutations in POLR3A, with the mutation in each causing a single amino acid change (of note, the mutations were different in each patient). As mutations in POLR3A are rare in cancer, this study suggests that mutated RNA polymerase III proteins are immunogens that initiate the anti-RNA polymerase III antibody response. Interestingly, there was loss of heterozygosity in five of eight (62.5%) of the anti-RNA polymerase antibody-positive patients. As this was not noted in cancers of the scleroderma patients with other antibody specificities, this finding is compelling evidence that the immune response against RNA polymerase III may shape how cancers evolve [43,44 && ]. It is noteworthy that antibodies from all the patients with POLR3A mutations recognized the wild type and mutated protein equally [44 && ]. This is consistent with evidence from Lin et al. [45] that modified self-antigens can initiate T-cell immune responses to altered antigens, producing B-cell responses that recognize the wild type and modified proteins equally. On the basis of this concept, we have proposed the following model of cancerinduced scleroderma (Fig. 3) [43] . Gene expression patterns similar to those of immature cells involved in tissue healing may result when normal cells become transformed. During this process, mutations in RNA polymerase III proteins may occasionally be generated. When these occur, they are found in some, but not all, of the cancer cells as they are not driver mutations. A mutant-specific T-cell response is initiated, which subsequently spreads to the wild-type protein. Although immune (2) . Occasionally, autoantigens become mutated (3); these are not driver mutations, and not all cancer cells have them. The first immune response is directed against the mutated form of the antigen (4), and may spread to the wild-type version (5) . Immune effector cells directed against the mutant (depicted in red) delete exclusively cancer cells containing the mutation (6) . Immune effector cells directed against the wild type (depicted in blue) delete cancer cells without the mutation and also cross-react with the patient's own tissues (particularly immature cells expressing high levels of antigen, found in damaged/repairing tissue) (7) . Once autoimmunity has been initiated, the disease is self-propagating. Immature cells (expressing high antigen levels) that repair the immune-mediated injury can themselves become the targets of the immune response, sustaining an ongoing cycle of damage/repair that provides the antigen source that fuels the autoimmune response. Reproduced with permission [43] .
Cancer and scleroderma Shah and Casciola-Rosen effector cells directed against mutant RNA polymerase III delete only those cancer cells with the mutation, those directed against the wild type form delete cancer cells without the mutation. In addition, the latter cross-react with self-tissue, thus initiating scleroderma. Autoimmunity subsequently becomes self-propagating, likely because immature cells expressing robust amounts of targeted antigens are themselves targeted by the immune response.
That the majority ($80%) of anti-RNA polymerase III antibody-positive scleroderma patients do not have an associated malignancy is informative [17, 43] . This indicates that an antitumor immune response may eradicate an occult malignancy in most of the scleroderma patients in this disease group. In those anti-RNA polymerase III antibody-positive patients in whom a malignancy does emerge, reasons for the temporal relationship between detection of both these diseases are discussed above.
In our original description of the short cancerscleroderma interval in patients with RNA polymerase III antibodies, we noted a second group of scleroderma patients with a similar temporal clustering [40 & ]. These patients were negative for the most commonly known scleroderma antibody specificities (i.e. ANA positive but having no antibodies against topoisomerase I, centromere proteins and RNA polymerase III). The data presented in Fig. 2 of this review (depicted as the 'Other group', and discussed above; see also reference [17] ) confirm our earlier observation in this regard. Together, these data indicate that other autoantigens of relevance to understanding the interface between scleroderma and cancer a wait to be defined [43] .
IMPLICATIONS FOR CANCER SCREENING AND SCLERODERMA THERAPEUTICS
These data strongly suggest that a subset of patients with scleroderma has cancer-induced autoimmunity, raising the question of whether early cancer diagnosis and treatment could induce remission of scleroderma. Further studies are required to identify the optimal cancer screening algorithm that should be performed in patients with new onset scleroderma. A potential framework to guide cancer screening is proposed in Fig. 4 [46] [47] [48] [49] . It is our standard practice to recommend age-appropriate and sex-appropriate cancer screening in scleroderma patients. This includes a comprehensive physical examination including palpating anterior and posterior cervical, supraclavicular, axillary, and inguinal lymph nodes; scanning the skin for atypical lesions, particularly those with asymmetry, indistinct borders, color variegation, or large diameter (>6 mm); careful visualization of the oral cavity; and palpating for thyroid nodules. For older patients developing new scleroderma, we would suggest updating a colonoscopy or Pap smear once even if the patient has passed the typical age for colon cancer (>75) or Pap smear (>65) screening. Currently, in the US, it remains controversial as to when and how often women should undergo mammographic screening for breast cancer. Because of the close temporal relationship between breast cancer and scleroderma onset, we recommend initiating annual mammography starting at 40 years of age. Further, targeted screening may be required based on the presence of specific risk factors as delineated in Fig. 4 . Finally, a subset of patients may benefit from aggressive cancer screening because of concern for paraneoplastic disease. We have denoted these patients as having a 'red flag' such as RNA polymerase III autoantibodies, an older age of scleroderma onset, atypical or treatment unresponsive disease, profound constitutional symptoms or weight loss, or a striking personal or family history of cancer. More extensive imaging, such as a CT of chest, abdomen and pelvis or whole body PET/CT scan, and laboratory testing (serum/ urine protein electrophoresis, peripheral blood flow cytometry and tumor markers) may be warranted in these patients.
CONCLUSION
Recent data strongly suggest that scleroderma may be a paraneoplastic disease in some patients. These emerging findings raise the intriguing possibility that cancer therapy might be effective at treating scleroderma. Although the cancerÀscleroderma relationship is most striking in patients with RNA polymerase III autoantibodies, the mechanisms and principles identified thus far likely apply to other patients with scleroderma, and more broadly across the spectrum of autoimmune rheumatic diseases. Further investigation is warranted to identify other relevant autoantigens that associate with paraneoplastic disease, particularly among patients developing scleroderma at an older age, as this may help define the population of patients who would benefit from enhanced cancer screening.
